Form D · Biotechnology
Partillion Bioscience Corp
Los Angeles, CA · CIK 0001960451
Offering snapshot reported Dec 30, 2022 · SEC filing
- Reported sold
- $4.87M Offering amount: $5.32M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 28, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2022 | Initial | $4,874,999 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-469239
Source: Form D, filed Dec 30, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Conley | Director |
| Joseph De Rutte | Director, Executive |
| Dino Di Carlo | Director |
| Eric Moessinger | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2360 Glendon Ave.
Los Angeles, CA, 90064
Los Angeles, CA, 90064